Latest Ratios: P/E Ratio -33.1x · EV/EBITDA 37.3x · ROE -12.0%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $94M | $60M | $33M | $26M | $33M | $70M | $45M | $79M | $94M | $117M | $89M |
| Enterprise Value | $93M | $58M | $36M | $26M | $34M | $59M | $39M | $73M | $86M | $81M | $59M |
| P/E Ratio → | -33.11 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.12 | 1.34 | 0.88 | 0.65 | 0.78 | 1.93 | 1.19 | 2.31 | 2.31 | 2.85 | 2.70 |
| P/B Ratio | 3.83 | 2.43 | 1.48 | 0.87 | 0.91 | 1.63 | 0.95 | 1.55 | 1.69 | 1.83 | 1.22 |
| P/FCF | 19.49 | 12.31 | — | 4.54 | 5.14 | 11.62 | 13.55 | 28.22 | — | — | — |
| P/OCF | 19.11 | 12.07 | — | 4.20 | 3.88 | 10.97 | 8.26 | 25.94 | 30.25 | — | 156.81 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.31 | 0.95 | 0.65 | 0.81 | 1.63 | 1.05 | 2.11 | 2.12 | 1.98 | 1.78 |
| EV / EBITDA | 37.28 | 23.36 | — | — | — | — | — | — | — | — | 61.10 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 12.05 | — | 4.56 | 5.32 | 9.79 | 11.89 | 25.83 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.0% | 85.0% | 82.6% | 84.7% | 78.3% | 75.5% | 76.9% | 78.4% | 81.9% | 82.1% | 82.0% |
| Operating Margin | -6.3% | -6.3% | -17.0% | -24.2% | -13.6% | -21.3% | -17.0% | -27.0% | -18.1% | -9.9% | -4.3% |
| Net Profit Margin | -6.4% | -6.4% | -17.1% | -15.9% | -13.3% | -9.7% | -8.9% | -10.3% | -17.1% | -19.4% | -2.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.0% | -12.0% | -25.0% | -19.3% | -14.2% | -7.8% | -6.8% | -6.6% | -11.7% | -11.6% | -1.3% |
| ROA | -3.7% | -3.7% | -8.2% | -7.2% | -6.3% | -3.9% | -3.3% | -3.3% | -6.8% | -8.5% | -1.0% |
| ROIC | -8.6% | -8.6% | -17.7% | -21.5% | -12.4% | -15.8% | -11.2% | -15.1% | -14.6% | -8.6% | -2.6% |
| ROCE | -6.6% | -6.6% | -13.2% | -16.2% | -8.8% | -11.3% | -8.4% | -11.2% | -9.2% | -5.3% | -1.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 0.91 | 0.63 | 0.58 | 0.38 | 0.41 | 0.42 | 0.36 | 0.15 | 0.06 |
| Debt / EBITDA | 4.08 | 4.08 | — | — | — | — | — | — | — | — | 4.25 |
| Net Debt / Equity | — | -0.05 | 0.12 | 0.00 | 0.03 | -0.26 | -0.12 | -0.13 | -0.14 | -0.56 | -0.42 |
| Net Debt / EBITDA | -0.51 | -0.51 | — | — | — | — | — | — | — | — | -31.55 |
| Debt / FCF | — | -0.26 | — | 0.02 | 0.19 | -1.83 | -1.66 | -2.39 | — | — | — |
| Interest Coverage | -5.63 | -5.63 | -9.68 | -8.41 | -8.52 | -55.74 | -23.92 | -36.74 | -54.17 | -40.71 | -11.55 |
Net cash position: cash ($11M) exceeds total debt ($10M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.01 | 1.01 | 1.15 | 1.28 | 1.60 | 2.37 | 1.95 | 2.08 | 2.69 | 3.88 | 4.43 |
| Quick Ratio | 0.84 | 0.84 | 1.03 | 1.11 | 1.26 | 1.93 | 1.53 | 1.71 | 1.69 | 3.50 | 4.07 |
| Cash Ratio | 0.31 | 0.31 | 0.57 | 0.65 | 0.69 | 1.40 | 0.96 | 1.17 | 1.30 | 2.83 | 3.39 |
| Asset Turnover | — | 0.58 | 0.50 | 0.48 | 0.45 | 0.43 | 0.39 | 0.33 | 0.36 | 0.44 | 0.35 |
| Inventory Turnover | 1.07 | 1.07 | 1.65 | 1.32 | 0.92 | 1.05 | 0.81 | 0.84 | 0.27 | 1.09 | 1.11 |
| Days Sales Outstanding | — | 138.92 | 112.79 | 90.05 | 114.37 | 69.76 | 120.67 | 83.42 | 70.28 | 74.46 | 81.01 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 5.1% | 8.1% | — | 22.0% | 19.5% | 8.6% | 7.4% | 3.5% | — | — | — |
| Buyback Yield | 0.3% | 0.4% | 1.7% | 2.9% | 3.2% | 2.0% | 4.1% | 4.4% | 3.1% | 3.2% | 2.8% |
| Total Shareholder Yield | 0.3% | 0.4% | 1.7% | 2.9% | 3.2% | 2.0% | 4.1% | 4.4% | 3.1% | 3.2% | 2.8% |
| Shares Outstanding | — | $15M | $14M | $14M | $15M | $15M | $15M | $15M | $16M | $16M | $16M |
Persistent Operating Cash Burn
According to recent market data, CPIX trades at a P/S of 2.27, which appears to price in significant optionality for the ifetroban pipeline rather than the underlying performance of its legacy hospital portfolio, as evidenced by the negative TTM P/E of -35.53 and lack of forward earnings visibility.
The valuation multiples suggest that investors are currently valuing the company as a clinical-stage biotech rather than a specialty pharmaceutical firm. Given the persistent operating losses, traditional metrics like P/E are non-informative, and the EV/EBITDA of 40.05 indicates that the market is willing to pay a substantial premium for potential future breakthroughs despite the current lack of profitability.
As reported in financial statements, the company's ROIC has remained consistently negative, reaching -10.8% in 2026Q1, which suggests that the current business model is failing to generate returns above the cost of capital due to the heavy fixed-cost burden of its commercial infrastructure.
The decay in ROIC over the last ten quarters highlights the difficulty of scaling a niche branded portfolio without achieving sufficient operating leverage. Investors should monitor whether the company can pivot toward a more capital-efficient model, as the current trend indicates that invested capital is being eroded rather than compounded.
Based on the reported figures, the company's cash conversion cycle remains deeply negative, with a 2026Q1 reading of -391 days, primarily driven by an exceptionally high DPO that suggests a reliance on extended payment terms with suppliers to manage liquidity constraints.
The extreme DPO figures indicate that the company is effectively using its suppliers as a source of interest-free financing, which is a common but risky strategy for firms with limited cash flow. The volatility in DSO and DIO further suggests that inventory management and collections are not yet optimized, creating potential for lumpy cash flow realizations.
According to recent SEC filings, CPIX has maintained a relatively conservative capital structure, with a D/E ratio of 0.47 as of 2026Q1, which provides a buffer against interest rate volatility despite the company's ongoing inability to generate consistent positive operating income.
While the debt-to-equity ratio has improved from previous periods, the negative interest coverage ratio of -36.46 in 2026Q1 warrants caution, as it indicates that the company is not currently generating enough operating profit to cover its interest obligations. This suggests that the balance sheet's health is more a result of debt repayment than operational success.
The P/E ratio is the most commonly misapplied metric for CPIX, as it obscures the company's true economic potential by focusing on accounting net income that is heavily distorted by R&D investments and non-recurring expenses related to the ifetroban clinical program, according to recent financial disclosures.
Investors should instead focus on EV/Revenue or adjusted EBITDA, which better reflect the underlying cash-generating capacity of the branded hospital portfolio. Relying on P/E in this context leads to a distorted view of the company's valuation, as it fails to account for the high-optionality nature of the R&D pipeline.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CPIX stock.
Cumberland Pharmaceuticals Inc.'s current P/E ratio is -33.1x. The historical average is 56.2x.
Cumberland Pharmaceuticals Inc.'s current EV/EBITDA is 37.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.6x.
Cumberland Pharmaceuticals Inc.'s return on equity (ROE) is -12.0%. The historical average is 2.3%.
Based on historical data, Cumberland Pharmaceuticals Inc. is trading at a P/E of -33.1x. Compare with industry peers and growth rates for a complete picture.
Cumberland Pharmaceuticals Inc. has 85.0% gross margin and -6.3% operating margin.
Cumberland Pharmaceuticals Inc.'s Debt/EBITDA ratio is 4.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.